NEXMED

GLP-1 and Addiction: Can They Reduce Cravings for Alcohol and Cigarettes?

Do GLP-1 medications reduce cravings for alcohol and cigarettes? What studies show (especially for alcohol), the mechanism, and the essential caveats.

Nexmed Editorial · Updated 11 September 2026
GLP-1 and Addiction: Can They Reduce Cravings for Alcohol and Cigarettes?

Beyond weight loss, GLP-1 class medications (semaglutide — Ozempic, Wegovy; tirzepatide — Mounjaro) have raised a fascinating question: can they also reduce cravings for alcohol, cigarettes, or other compulsions? More and more patients report exactly that, and research has begun to test the phenomenon. Here is what is known, in a balanced way and without the hype.

In short: the idea that GLP-1 medications reduce cravings is real and scientifically plausible, and for alcohol it already has support from the first randomized trials. But for any form of addiction, these medications are not approved, the human evidence is still limited and early, and the effect seems clearest in people who also have obesity. This is an active area of research — not an established treatment. Don't self-medicate to quit drinking or smoking.

The phenomenon: what patients report

Many people taking these medications for weight or diabetes spontaneously report that their desire for alcohol, cigarettes, and sometimes compulsive behaviors (shopping, gambling) has decreased. The observation is consistent — it shows up in patient accounts, social media analyses, real-world data, and now in studies. It is a genuinely reported effect, not an invention. But how solid the evidence is varies a lot from one behavior to another:

  • Alcohol — the strongest evidence (robust animal studies, large observational data, two small randomized trials).
  • Smoking/nicotine — weaker evidence (mostly observational).
  • Gambling, compulsive shopping — the weakest (essentially just anecdotes + a plausible mechanism).

Alcohol: what the studies show

In animals

In mice and even in primates, GLP-1 agonists reduce alcohol intake, reduce the motivation to drink, and reduce relapse, by dampening the "reward" effect of alcohol. This is the most consistent part of the field — but it is animal data.

Real-world data

A large retrospective study (2024) found that, among tens of thousands of patients with obesity, semaglutide was associated with roughly half the risk of developing, or relapsing into, an alcohol use disorder compared with other weight-loss medications — a pattern also replicated in hundreds of thousands of patients with diabetes. Note: because it is observational, it shows an association, not proven causation.

Randomized trials: the nuances matter

Precision is needed here, because the results are not uniform:

  • An older trial (exenatide, 2022) was negative overall — the drug did not reduce heavy drinking days compared with placebo. Only in an exploratory subgroup with obesity did a benefit appear, while leaner people seemed not to benefit. This is the origin of the recurring idea that the effect is clearest when obesity is also present.
  • A semaglutide trial (2025, 48 participants) showed a significant reduction in alcohol craving and in the amount drunk per occasion, although it did not significantly change how often people drank. The authors concluded that it warrants larger trials — not definitive proof.
  • The newest trial (2026, about 108 participants with moderate-to-severe alcohol use disorder and obesity, in Denmark) showed a greater reduction in heavy drinking days in the semaglutide group compared with placebo. It is the first trial in patients actively seeking treatment — but still relatively small, and the population also had obesity.

An honest summary for alcohol: the animal evidence is strong, the observational evidence is encouraging, and in humans we have two small positive randomized trials (2025, 2026) plus an older negative one. In total, a few hundred people in randomized trials, followed for at most half a year, with a clearer effect in those who also have obesity. Promising, but unproven — it doesn't change medical practice yet.

Smoking and other behaviors: more uncertain

Smoking/nicotine. In animals, GLP-1 agonists reduce nicotine-seeking. In humans, the evidence is mostly observational or from secondary analyses, not dedicated smoking-cessation trials. The signal is plausible, but the effect is uncertain, and dedicated randomized trials with semaglutide are still ongoing.

Gambling, compulsive shopping. Here we essentially have only anecdotes and mechanistic plausibility. Some users report less compulsive shopping or less interest in betting, but there are no controlled clinical trials demonstrating efficacy for behavioral addictions.

Why it might work: the mechanism

GLP-1 is a gut-brain hormone, and its receptors are also found in the brain's reward and motivation regions — the same circuits that fuel cravings for food, alcohol, or nicotine. In animal studies, these medications blunt the dopamine surge that alcohol or nicotine normally triggers, reducing the reward signal and the "wanting."

The plausible unifying idea: these medications may "turn down" a shared reward pathway, which would explain why the same molecule affects cravings for food, alcohol, and possibly other compulsions. An important caveat: the detailed mechanism in humans is not fully mapped — most of the certainty comes from animal studies. It is the leading hypothesis, not an established fact. For background on this drug class, see GLP-1 and the heart/kidneys.

The essential warning

This is the message to remember above all else:

  • They are not approved for any addiction. Semaglutide and tirzepatide are approved for diabetes and weight management — not for alcohol, smoking, or behavioral addictions. Using them for this purpose is experimental/off-label.
  • The evidence is early: small randomized trials, short follow-up, unknown durability after stopping, and a clearer effect in people with obesity.
  • Don't self-medicate, and don't seek out these medications just to quit drinking or smoking outside a clinical trial or a specialist's guidance.
  • Proven treatments for addiction already exist: for alcohol (medications such as naltrexone, acamprosate, and disulfiram, plus counseling) and for smoking (varenicline, nicotine replacement, bupropion, behavioral support). GLP-1 drugs do not replace them.

Safety in this context

The usual side effects of the class apply regardless of why the medication is used: nausea, vomiting, diarrhea, constipation, risk of dehydration, rarely pancreatitis, gallbladder problems, plus contraindications (history of medullary thyroid carcinoma, MEN2). One specific precaution: people who drink heavily may have nutritional or liver problems or a risk of pancreatitis, and combining heavy drinking with digestive side effects and dehydration requires medical supervision — one more reason not to do this on your own. On the mental health side, monitoring remains prudent, especially in people with addictions, who have a higher baseline risk. See also Wegovy and Mounjaro side effects.

What this means for patients

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are approved for diabetes and/or weight management — not for addiction. Any use for this purpose would be off-label. Interestingly, the most recent randomized trial for alcohol was carried out in the European Union (Denmark). If you are struggling with an addiction, talk to a doctor (your primary care doctor, an addiction specialist, or a psychiatrist): addiction treatment should follow established care pathways, not self-medication with GLP-1 drugs.

If you want a clear record to discuss with your doctor, a GLP-1 tracker such as Reko (partner app, iPhone) logs each dose, the side effects you notice and your weight over time.

Conclusion

The link between GLP-1 medications and reduced cravings is one of the most interesting research directions in medicine today — real, plausible, and, for alcohol, supported by the first randomized trials. But enthusiasm must not get ahead of the evidence: nothing is approved for addiction, the data are early, and established treatments remain the first choice. If the future confirms these results, we may have a valuable new tool. For now, the right message is informed optimism, not "GLP-1 cures addiction."

Frequently asked questions

Do Ozempic/Wegovy reduce alcohol cravings? Many people report this, and the first randomized trials (2025, 2026) showed reduced craving and less alcohol consumed, especially in those who also have obesity. The evidence is promising but early; the medications are not approved for alcohol use.

Do they help you quit smoking? Possibly, but the human evidence is weaker (mostly observational). Dedicated trials are still ongoing. It is not an approved smoking-cessation method.

Do they work for gambling or compulsive shopping? There are only anecdotes and mechanistic plausibility, with no clinical trials proving efficacy. For now, it's speculative.

Why would they reduce cravings? GLP-1 receptors are also found in the brain's reward areas; in animal studies, these medications blunt the dopamine surge triggered by alcohol or nicotine, reducing the "wanting." This is the leading hypothesis, based mainly on animal data.

Can I take these medications to quit drinking? Not on your own initiative. They are not approved for addiction, and such use would be off-label. Proven treatments for addiction exist; talk to a specialist.

Are they safe in this context? They have the same side effects and contraindications as usual (digestive effects, dehydration, rare pancreatitis, MEN2). There are additional precautions for people who drink alcohol. They require medical supervision.

Does the effect on cravings go away if I stop the medication? Probably, but this isn't known for sure — the durability of the effect after stopping hasn't been studied enough. As with weight, part of the effect may fade when treatment is stopped. This is one of the reasons larger, longer trials are needed.

Read next


Educational material, updated September 2026. It does not replace medical advice. These medications are not approved for treating addiction; any use must be by prescription and under a doctor's supervision.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1